Apnimed prices its initial public offering at $16 per share. Multiple reports say the company’s IPO is upsized and that the offering raises $192 million in gross proceeds. The coverage across outlets is aligned on the key deal terms, including the final share price and the total capital raised. After pricing, the IPO proceeds through its standard post-pricing process, with the company moving toward listing based on the final terms disclosed at pricing. Neither report provides additional, outlet-specific details in the provided excerpts beyond the pricing and amount raised. Overall, the sources agree that Apnimed completes IPO pricing at $16 per share and that the upsized offering generates $192 million, reflecting both the final per-share pricing and the increased size of the deal compared with initial expectations.